[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephrolithiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephrolithiasis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,60,81,109,140,159,175,199,223,244,270,305,334,355,385,404,429,459,490,513,538,561,584,605,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100645126","access-sheaths-with-aspiration-for-renal-retrograde-surgery-randomized-comparative-outcomes-100645126",false,"NCT07678255","Access Sheaths With Aspiration for Renal RetrOgrade Surgery, Randomized CompArative Outcomes","ACCESS SHEATHS WITH ASPIRATION FOR RETROGRADE RENAL SURGERY, RANDOMIZED COMPARATIVE OUTCOMES","ARROCA01","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of intrarenal lithiasis with maximum stone diameter of 1-3 cm on preoperative non-contrast abdomino-pelvic CT scan\n* Candidate for treatment by flexible ureteroscopy (RIRS) as indicated by the treating urologist\n* Attended at the Department of Urology, Hospital Universitario Virgen del Rocío (Seville, Spain)\n* Willing and able to provide written informed consent\n* Able to comply with the study follow-up schedule (CT scan at 1 and 3 months post-intervention)\n\nExclusion Criteria:\n\n* Active urinary tract infection or urosepsis at the time of the planned intervention\n* Known ureteral stricture precluding passage of a ureteral access sheath\n* Pregnancy\n* Prior urinary diversion incompatible with transurethral access (e.g., urinary conduit, neobladder)\n* Bleeding disorder or anticoagulant\u002Fantiplatelet therapy that cannot be safely interrupted perioperatively\n* Stone diameter \\\u003C1 cm or \\>3 cm on preoperative CT\n* Inability to provide informed consent (cognitive impairment, language barrier without interpreter availability)\n* Simultaneous participation in another clinical trial that could interfere with the outcomes of this study","ALL","18 Years",{"count":21,"type":22},156,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether the ClearPetra ureteral access sheath (Coloplast) is more effective than the Navigator ureteral access sheath (Boston Scientific) in treating intrarenal kidney stones of 1-3 cm in adult patients undergoing flexible ureteroscopy (RIRS). The main questions it aims to answer are:\n\nDoes ClearPetra achieve a higher stone-free rate at 1 month post-intervention compared to Navigator, as assessed by non-contrast abdominal-pelvic CT scan?\n\nDoes ClearPetra reduce total surgical time compared to Navigator?\n\nDoes ClearPetra lower the retreatment rate at 3 months compared to Navigator?\n\nDoes ClearPetra present a rate of clinically significant complications (Clavien-Dindo ≥ II) that is lower than or similar to Navigator?\n\nResearchers will compare flexible ureteroscopy using the ClearPetra vacuum-assisted flexible ureteral access sheath to flexible ureteroscopy using the Navigator standard rigid ureteral access sheath, to see if ClearPetra leads to higher stone clearance rates while maintaining a comparable safety profile.\n\nParticipants will:\n\nUndergo flexible ureteroscopy (RIRS) using one of two randomly assigned ureteral access sheaths (ClearPetra or Navigator), determined by computer-generated randomization immediately before surgery\n\nHave a non-contrast abdominal-pelvic CT scan at 1 month post-intervention to assess stone-free status\n\nHave a non-contrast abdominal-pelvic CT scan at 3 months post-intervention to evaluate residual fragments and the need for retreatment\n\nAttend follow-up visits at 1 month and 3 months post-surgery for clinical assessment and complication recording\n\nThe study will be conducted at the Urology Department of Hospital Universitario Virgen del Rocío (Seville, Spain), a tertiary reference centre. A total of 156 patients will be randomized in a 1:1 ratio (78 per group), with pre-defined subgroup analyses stratified by stone size (1-2 cm vs. \\>2 cm). The outcome assessor evaluating CT images for stone-free rate will be blinded to treatment allocation (single-blind).",[28,29,30,31],"Urolithiasis","Nephrolithiasis","Kidney Calculi","Ureteroscopy",[33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Flexible ureteroscopy","Retrograde intrarenal surgery","RIRS","Ureteral access sheath","ClearPetra","Navigator","Stone-free rate","Laser lithotripsy","Intrarenal lithiasis","Vacuum-assisted sheath","Clavien-Dindo","Stone fragmentation","Endourology","Urinary tract calculi","NOT_YET_RECRUITING","2026-06-25",{"date":50,"type":51},"2026-07-01","ACTUAL",{"date":53,"type":22},"2026-09-15",{"date":55,"type":22},"2030-05",{"name":57,"class":58},"Hospitales Universitarios Virgen del Rocío","OTHER",1,{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":59},"100644022","tract-closure-in-pcnl-100644022","NCT07668817","Tract Closure in PCNL","Defining the Role of Hemostatic Agents in Percutaneous Nephrolithotomy: A Randomized Controlled Trial of Tract Closure Techniques","Inclusion criteria:\n\n* At least one stone ≥ 1.2cm\n* Scheduled to undergo planned PCNL\n* Age ≥ 18 years\n\nExclusion criteria:\n\n* Unable to provide informed consent\n* Pre-existing nephrostomy tube\n* Multi access cases\n* Stone in calyceal diverticulum\u002Fhydrocalyx\n* Preoperatively planned overnight admission for any reason\n* Infundibular stenosis\n* Coagulation disorders\n* Other significant anatomic abnormalities",{"count":68,"type":22},92,[25],"This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.",[29],"RECRUITING","2026-06-21",{"date":48,"type":51},{"date":76,"type":22},"2026-07",{"date":78,"type":22},"2028-06",{"name":80,"class":58},"Icahn School of Medicine at Mount Sinai",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":59},"100637205","supine-vs-prone-pcnl-for-large-renal-stones-a-randomized-trial-in-yemen-100637205","NCT07627503","Supine vs. Prone PCNL for Large Renal Stones: A Randomized Trial in Yemen.","Comparative Evaluation of Early Postoperative Complications, Cost-Effectiveness, and Patient-Centered Outcomes Following Supine and Prone Standard Percutaneous Nephrolithotomy (PCNL): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18-70 years.\n* Diagnosis of solitary or multiple renal stones with a cumulative diameter greater than 2 cm, confirmed by imaging (CT KUB).\n* Patients eligible for standard PCNL (24-30 Fr).\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Willingness and ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with active urinary tract infection (UTI) not responding to antibiotics.\n* Patients with bleeding diathesis or on anticoagulant therapy that cannot be safely discontinued.\n* Patients with anatomical abnormalities of the kidney or urinary tract that preclude standard PCNL.\n* Pregnant women.\n* Patients with severe cardiopulmonary disease where general anesthesia or prolonged surgical positioning is contraindicated.\n* Patients with a history of previous ipsilateral renal surgery.\n* Patients unwilling or unable to comply with follow-up protocols.","70 Years",{"count":90,"type":22},140,[25],"The goal of this clinical trial is to compare the safety, cost-effectiveness, and patient recovery of two different surgical positions for percutaneous nephrolithotomy (PCNL) in adults aged 18 to 70 years who have kidney stones larger than 2 cm. The main questions it aims to answer are:\n\n* Does the supine (lying on the back) surgical position result in fewer early postoperative complications than the traditional prone (lying on the stomach) position?\n* Does the supine position reduce the total surgery time, direct hospital costs, and postoperative pain?\n\nResearchers will compare patients assigned to undergo PCNL in the supine position to those assigned to the prone position to see if the supine approach offers a safer, more cost-effective, and more comfortable recovery.\n\nParticipants will:\n\n* Undergo standard PCNL surgery to remove their kidney stones in either the supine or prone position.\n* Have their pain levels, surgery time, and any early surgical complications monitored during their hospital stay.\n* Complete brief questionnaires regarding their overall surgical satisfaction and quality of life at 1 month and 3 months after the procedure.",[30,29],[95,96,97,98,99],"PCNL","Percutaneous Nephrolithotomy","Kidney Stones","Supine PCNL","Prone PCNL","2026-06-03",{"date":102,"type":51},"2026-06-05",{"date":104,"type":22},"2026-06-01",{"date":106,"type":22},"2027-06-30",{"name":108,"class":58},"Sana'a University",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":18,"minAge":19,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":128,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100592122","endogenous-oxalate-synthesis-in-idiopathic-calcium-oxalate-kidney-stone-disease-100592122","NCT06989320","Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease","Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Formers","Inclusion Criteria:\n\n* age 18-80 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.\n* For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \\\u003C20%\n\nExclusion Criteria:\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria, Enteric (secondary) hyperoxaluria\n* Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled hypertension or diabetes\n* Diabetes type 1",true,"80 Years",{"count":119,"type":22},80,[25],"The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate.\n\nThe study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.\n\nParticipants will\n\ningest fixed diets containing low amounts of oxalate for 5 days ingest a soluble form of glycolate and vitamin C collect urine, blood, stool during the dietary and oral dosing portions of the study and also collect breath sample during the oral glycolate test",[97,30,28,123,29,124,125,126,127],"Urolithiasis, Calcium Oxalate","Nephrolithiasis, Calcium Oxalate","Oxalate Urolithiasis","Healthy","Healthy Volunteer",[129],"oxalate synthesis","2026-05-27",{"date":132,"type":51},"2026-05-29",{"date":134,"type":51},"2025-05-27",{"date":136,"type":22},"2031-12-31",{"name":138,"class":58},"University of Alabama at Birmingham",2,{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":116,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":158,"locationsCount":139},"100541567","gut-oxalate-absorption-in-calcium-oxalate-stone-disease-100541567","NCT06331546","Gut Oxalate Absorption in Calcium Oxalate Stone Disease","Gastrointestinal Oxalate Absorption in Calcium Oxalate Stone Disease","Inclusion Criteria:\n\n* age 18-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.\n* For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \\\u003C20%\n\nExclusion Criteria:\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria, Enteric (secondary) hyperoxaluria\n* Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled hypertension or diabetes\n* Diabetes type 1\n* Chronic NSAID use",{"count":119,"type":22},[25],"The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased absorption of dietary oxalate, which would lead to increased urinary excretion of oxalate.\n\nThe study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 5 days at a time\n* ingest a soluble form of oxalate and sugar preparations to test gut permeability\n* collect urine, blood, stool and breath sample during the fixed diets and the soluble oxalate test",[151,30,28,123,29,124,125,152,126],"Kidney Stone","Oxaluria",{"date":154,"type":51},"2026-05-28",{"date":156,"type":51},"2024-04-17",{"date":136,"type":22},{"name":138,"class":58},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":174,"locationsCount":139},"100541467","o-formigenes-colonization-in-calcium-oxalate-kidney-stone-disease-100541467","NCT06330246","O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease","Oxalobacter Formigenes Colonization in Calcium Oxalate Kidney Stone Formers","Inclusion Criteria\n\n* age 19-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* First time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available\n* Not colonized with Oxalobacter formigenes\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during fixed diet phases.\n* If on medications for stone prevention (e.g. thiazides, citrate, allopurinol), stable dose regimen for at least 2 weeks prior to and during study\n\nExclusion Criteria\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria\n* Liver, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled Hypertension or diabetes\n* Diabetes type 1\n* Current Colonization with Oxalobacter formigenes",{"count":167,"type":22},40,[25],"The goal of this trial is to test if colonization with the gut bacteria Oxalobacter formigenes leads to a reduction in urinary oxalate excretion in patients with calcium oxalate kidney stone disease.\n\nThe study will recruit adult participants with a history of calcium oxalate kidney stones who are not colonized with Oxalobacter formigenes.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 4 days at a time\n* collect urine, blood and stool samples during the fixed diets\n* ingest a preparation of live Oxalobacter formigenes to induce colonization with Oxalobacter formigenes",[151,30,28,123,29,124,125,152],{"date":154,"type":51},{"date":156,"type":51},{"date":136,"type":22},{"name":138,"class":58},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100566327","phase-3-trial-to-assess-the-efficacy-of-empagliflozin-and-personalized-dietary-counseling-for-kidney-stone-prevention-100566327","NCT06653738","Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention","Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial","EMPASTONE","Inclusion criteria:\n\n1. Written, informed consent.\n2. Age 18 years or older.\n3. Recurrent kidney stone disease with 2 or more stone episodes in the last 10 years prior to randomization.\n4. Last kidney stone containing 50% or more of CaOx, CaP or a mixture of both.\n5. If taking guideline-recommended medications for kidney stone prophylaxis (e.g. citrate salts), patients must have been on a stable regimen for at least 60 days before randomization and willing to remain on this stable regimen for the duration of the study.\n\nExclusion criteria:\n\n1. Known history of secondary or Mendelian causes of calcium nephrolithiasis\n2. Type I diabetes mellitus\n3. History of ketoacidosis\n4. Chronic Kidney Disease (CKD) stage 4 or 5 (defined as CKD-EPI eGFR \\\u003C30 mL\u002Fmin)\n5. Kidney transplant recipient\n6. History of recurrent urinary tract infections, defined as \\>3 episodes within the year prior to randomization\n7. Heart failure. Symptomatic patients with suspected heart failure must be evaluated before study enrollment\n8. Treatment with an SGLT2i within 4 weeks prior to randomization.\n9. Active cancer treatment\n10. Pregnancy and\u002For breastfeeding. Women of childbearing potential (i.e., premenopausal women who have not undergone surgical sterilization and are sexually active with a male partner) must have a negative urine or blood pregnancy test prior to enrollment\n11. Known allergy to the study drug\n12. Inability to understand and follow the study procedures\n13. Vulnerable individual, e.g. individual incapable of judgement or currently incarcerated or otherwise institutionalized (priosner), or refugee\n14. Concomitant participation in another interventional clinical trial within 4 weeks prior to randomization and during the current trial\n15. Prior enrollment in the EMPASTONE trial",{"count":184,"type":22},400,[186],"PHASE3","The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones.\n\nStudy interventions:\n\n* Empagliflozin 10 mg once daily per os for 36 months\n* Personalized dietary counseling for 36 months.\n\nControl interventions:\n\n* Placebo once daily per os for 36 months\n* Generic dietary counseling for 36 months.",[151,29,189],"Dietary Exposure","2026-05-21",{"date":130,"type":51},{"date":193,"type":22},"2026-06",{"date":195,"type":22},"2030-09",{"name":197,"class":58},"Insel Gruppe AG, University Hospital Bern",21,{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":59},"100599706","hoyag-vs-tfl-in-minipcnl-with-clearpetra-100599706","NCT07087977","HoYAG vs TFL in miniPCNL With ClearPetra","Holmium:YAG Laser With MOSES Technology vs Thulium Fiber Laser in Supine Mini-percutaneous Nephrolithotomy With Vacuum-assisted Renal Access Sheath: A Prospective, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Males or females over 18 years of age\n2. Patients with kidney stones, with stone burden larger than 15 mm.\n3. Patients undergoing new percutaneous access with primary, supine, unilateral mini-PCNL.\n\n   Exclusion Criteria:\n4. Simultaneous use of more than 1 laser platform or other form of fragmentation (e.g., ultrasonic).\n5. Patients undergoing simultaneous treatment of contralateral kidney stones during the same procedure.\n6. Patients undergoing simultaneous treatment of ureteral stones during the same procedure.\n7. Pregnant patients.\n8. Presence of genitourinary anatomical abnormalities.\n9. Uncorrected coagulopathy.\n10. External urinary catheters.\n11. Immunosuppressed patients.\n12. Non-elective procedures.",{"count":207,"type":22},150,[25],"Mini percutaneous nephrolithotripsy is the treatment of choice for kidney stones over 2cm. This procedure commonly uses laser energy for breaking the stones, and among possible laser platforms, Hoyag and thulium fiber laser are FDA approved. Recently, this procedure has also included the use of vacuum assisted renal access sheaths, which allows suction to be employed together with the breaking of stones. This study intends to compare outcomes when using either laser platforms with suction sheaths in participants undergoing mini percutaneous nephrolithotripsy for the treatment of kidney stones.",[29,151],[29,151,37,212,213],"HoYAG","TFL","2026-05-01",{"date":216,"type":51},"2026-05-06",{"date":218,"type":51},"2025-08-22",{"date":220,"type":22},"2027-12-01",{"name":222,"class":58},"University of Kansas Medical Center",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":116,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":59},"100560401","evaluation-of-the-lithovue-elite-ureteroscope-with-intra-renal-pressure-monitoring-technology-examination-of-surgeon-behavior-and-post-operative-outcomes-100560401","NCT06576661","Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Behavior and Post-operative Outcomes","ELITE","Inclusion Criteria:\n\n* Males or females over 18 years of age\n* Undergoing flexible ureteroscopy to address urinary stones located in the proximal ureter or kidney\n* Total stone burden over 2 cm\n\nExclusion Criteria:\n\n1. Undergoing bilateral stone treatment during the same procedure\n2. Patients with known genitourinary anatomical abnormalities\n3. Uncorrected coagulopathy\n4. Patients with urinary diversions\n5. Chronic external urinary catheters\n6. Women who are pregnant\n7. Immunosuppressed patients",{"count":119,"type":22},[25],"The goal of this study is to evaluate the influence of real-time intrarenal pressure measurement availability on surgeons' behavior during ureteroscopy while using the ureteroscope LithoVue Elite.",[151,29],[235,236],"Intrarenal Pressure","LithoVue Elite",{"date":238,"type":51},"2026-05-04",{"date":240,"type":51},"2025-01-28",{"date":242,"type":22},"2026-11-01",{"name":222,"class":58},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":59},"100598523","comparing-efficiency-and-stone-free-rates-mini-pcnl-vs-flex-urs-100598523","NCT07072598","Comparing Efficiency and Stone-Free Rates Mini PCNL vs Flex URS","Comparing Efficiency and Stone-Free Rates After Mini-Percutaneous Nephrolithotomy and Flexible Ureteroscopy With Suction Access Sheaths","Inclusion Criteria:\n\n* Patients 18 years or older\n* Have a CT scan showing renal stones 1-3cm in length\n* Patients who will be able to read, understand, and complete patient questionnaires\n\nExclusion Criteria:\n\n* Pregnant individuals\n* Those with anomalous renal anatomy\n* Patients with a urinary diversion (ex: Ileal conduit, reservoir, bladder substitute, etc.)\n* Any condition rendering patient medically unfit to undergo either procedure (Bleeding diasthesis)\n* Patients who lack decisional capacity\n* Patients who are non-english speakers\\*\n\n  * Non-recruitment of non-english speakers is due to the study being a small pilot study that is used to assess the stone free rate for patients treated with a ureteroscopy or mini-PCNL using ClearPETRA suction access sheaths in a small portion of our patient population seeking treatment for stones. The team also does not possess the bandwidth or personnel to consent patients who are non-English speaking.",{"count":119,"type":22},[25],"The objective of the study is to compare the stone free rates with ureteroscopy utilizing the ClearPETRA suction ureteral access sheath, and mini-PCNL; both procedures and ClearPETRA sheaths are standard of care and are used regularly for stone treatment. Our primary objective is to assess the complete stone free rate with both procedures.",[97,29,28],[256,31,257,258,259,260],"kidney stone","Mini-PCNL","ClearPETRA","kidney stone interventional treatment","kidney stone 1cm-3cm","2026-04-26",{"date":263,"type":51},"2026-04-30",{"date":265,"type":22},"2026-04-25",{"date":267,"type":22},"2027-12",{"name":269,"class":58},"Northwestern University",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":278,"maxAge":88,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":288,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":59},"100626454","effect-of-comprehensive-spa-care-on-kidney-and-urological-conditions-a-clinical-study-in-adult-patients-100626454","NCT07435844","Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients","Objective Assessment of the Effect of Comprehensive Spa Care on Patients With Chronic Kidney and Urological Diseases: A Prospective Interventional Clinical Study","Uro-Nefro","Inclusion Criteria:\n\n* Male or female aged 40 to 70 years\n* Prescribed comprehensive spa care (KLP) for one of the following indications: recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract resistant to antibiotic and pharmacological treatment, with at least 12 months of continuous urological care (indication VIII\u002F1); cystic kidney disease (indication VIII\u002F1); nephrolithiasis without urinary tract obstruction or nephrocalcinosis (indication VIII\u002F2); conditions after kidney or urinary tract surgery, including endovesical procedures, complicated prostatectomy, nephrolithotripsy, or recovery after extracorporeal shock wave lithotripsy (indication VIII\u002F3); chronic prostatitis or chronic prostatovesiculitis resistant to pharmacological and antibiotic treatment, with at least 12 months of continuous urological care (indication VIII\u002F4)\n* Able to walk from the sanatorium to the colonnade and back three times daily\n* Willing to follow the treatment plan\n* Signed informed consent\n\nExclusion Criteria:\n\n* Contraindications according to Czech Decree No. 2\u002F2015 Coll. on spa treatment criteria (pregnancy, acute illness, etc.)\n* Significant mobility limitation or severe neuropathy preventing daily walks to the colonnade\n* Significant obesity or inability to briefly hold breath (required for ultrasound examination)\n* Alcohol intake exceeding 20 g of ethanol per day\n* Nephrolithiasis with urinary tract obstruction\n* History of esophageal or gastric variceal bleeding\n* Severe comorbidities that could affect treatment outcomes\n* Active oncological disease\n* Unwillingness to adhere to the treatment plan","40 Years",{"count":207,"type":22},[25],"This is a single-arm, pretest-posttest study evaluating the effects of a 21-day comprehensive spa care (Komplexní lázeňská léčebně rehabilitační péče, KLP) on patients with nephrological and urological conditions treated at a spa facility in Mariánské Lázně, Czech Republic.\n\nThe study enrolls 150 adult patients (75 men and 75 women), aged 40-70 years, who are prescribed KLP for indications VIII\u002F1 (recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract), VIII\u002F2 (nephrolithiasis without urinary tract obstruction, nephrocalcinosis), VIII\u002F3 (conditions after kidney and urinary tract surgery), and VIII\u002F4 (chronic prostatitis or prostatovesiculitis resistant to pharmacological treatment).\n\nThe spa treatment consists of the use of natural healing resources of Mariánské Lázně, including a mineral spring drinking cure, balneotherapy (mineral water baths), peloid therapy, carbon dioxide therapy, climatotherapy, exercise therapy, and dietotherapy. The standard treatment duration is 21 days, during which each patient receives a total of 63 therapeutic procedures and drinks mineral spring water three times daily.\n\nPatients undergo assessments at the beginning (days 1-3) and at the end (days 19-21) of their treatment. Assessments include physical examination, abdominal and urinary tract ultrasound, blood and urine sampling with laboratory analysis, body composition measurement using bioelectrical impedance analysis (InBody), and psychometric questionnaire surveys.\n\nThe primary aim of the study is to objectively assess the therapeutic effect of comprehensive spa care on nephrological and urological diseases by comparing pre-treatment and post-treatment clinical, laboratory, and patient-reported outcomes.\n\nThe study was approved by the Ethics Committee of the University Hospital and Faculty of Medicine in Pilsen (decision of November 2, 2023, ref. no. 437\u002F23).",[283,284,29,285,286,287],"Urologic Diseases","Urinary Tract Infections","Nephrocalcinosis","Prostatism","Kidney Diseases",[289,290,291,292,293,294,295],"Balneotherapy","Spa Treatment","Mineral Water Drinking Cure","Mariánské Lázně","Nephrology","Urology","comprehensive spa care","2026-04-21",{"date":298,"type":51},"2026-04-24",{"date":300,"type":51},"2026-04-07",{"date":302,"type":22},"2027-04-30",{"name":304,"class":58},"Institute of Spa and Balneology, public research institution",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":312,"maxAge":117,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":330,"leadSponsor":332,"locationsCount":59},"100634099","effect-of-complete-suction-induced-collapse-of-the-renal-collecting-system-at-the-end-of-rirs-on-early-postoperative-outcomes-100634099","NCT07535281","Effect of Complete Suction-Induced Collapse of the Renal Collecting System at the End of RIRS on Early Postoperative Outcomes","Effect of Complete Suction-Induced Collapse of the Renal Collecting System at the End of Retrograde Intrarenal Surgery on Early Postoperative Outcomes: A Prospective Randomized Study","Inclusion Criteria:\n\n* Patients aged 20 to 80 years.\n* Patients diagnosed with kidney stones and scheduled for retrograde intrarenal surgery (RIRS).\n* Patients who have voluntarily signed the written informed consent form\n\nExclusion Criteria:\n\n* Participation in another clinical trial (drug or device) within 1 month prior to enrollment.\n* Congenital abnormalities of the urinary or reproductive system.\n* Presence of a pre-placed ureteral stent (pre-stenting) at the time of surgery.\n* Solitary kidney.\n* Uncontrolled urinary tract infection.\n* History of ureteral reconstruction on the affected side.\n* Pregnancy.\n* Uncorrectable bleeding diathesis or ongoing therapeutic anticoagulation therapy.\n* Contraindications to general anesthesia.\n* Other conditions that the investigator deems inappropriate for participation in the study.","20 Years",{"count":314,"type":22},90,[25],"The purpose of this study is to evaluate whether actively suctioning the renal collecting system to induce a \"collapse\" state at the end of retrograde intrarenal surgery (RIRS) can reduce postoperative pain and infection in patients with kidney stones. Participants will be randomly assigned to either the experimental group (suction-induced collapse) or the control group (standard drainage). The study aims to determine if this simple surgical modification can improve early recovery outcomes and patient satisfaction.",[97,29,318],"Renal Calculi",[320,321,322,323,324,325],"retrograde intrarenal surgery","ureteral access sheath","suction","postoperative pain","infectious complications","renal collecting system","2026-04-20",{"date":328,"type":51},"2026-04-23",{"date":326,"type":51},{"date":331,"type":22},"2027-09",{"name":333,"class":58},"Kangdong Sacred Heart Hospital",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":59},"100633160","early-vs-delayed-extracorporeal-shock-wave-lithotripsy-for-residual-stones-after-percutaneous-nephrolithotomy-100633160","NCT07523074","Early vs Delayed Extracorporeal Shock Wave Lithotripsy for Residual Stones After Percutaneous Nephrolithotomy","Optimum Time for Extracorporeal Shock Wave Lithotripsy for Residual Stones After Percutaneous Nephrolithotomy: A Prospective Comparative Randomized Study","Inclusion Criteria:\n\n* Age 18-70 years.\n* Single or multiple residual renal stones ≤15 mm after PCNL.\n* Normal renal function (serum creatinine \\\u003C1.5 mg\u002FdL).\n* No active UTI.\n\nExclusion Criteria:\n\n* Bleeding disorders or anticoagulant therapy.\n* Obstructed drainage or active sepsis.\n* Stones \\>15 mm or requiring secondary PCNL.",{"count":342,"type":22},476,[25],"Residual renal stone fragments remain a common clinical issue following percutaneous nephrolithotomy (PCNL), with reported incidence ranging from 10% to 30%. These fragments may act as a nidus for recurrent stone formation, infection, or obstruction, necessitating further intervention. Extracorporeal shock wave lithotripsy (ESWL) is widely used as a non-invasive treatment option for such residual stones; however, the optimal timing of ESWL after PCNL remains unclear.\n\nEarly application of ESWL may enhance stone clearance before fragment embedding or encrustation occurs, but it could be associated with increased risk of bleeding or infection due to incomplete renal healing. Conversely, delayed ESWL allows for better tissue recovery but may permit stone growth or persistence of symptoms.\n\nThis prospective randomized comparative study aims to evaluate the optimal timing of ESWL after PCNL in patients with residual renal stones ≤15 mm. Eligible patients will be randomized into two groups: early ESWL (within 7-14 days after PCNL) and delayed ESWL (after 3-4 weeks). The primary outcome is the stone-free rate at 3 months, while secondary outcomes include complication rates, pain scores, renal function changes, and the need for additional interventions.\n\nThe results of this study are expected to provide evidence-based guidance on the ideal timing of ESWL following PCNL to maximize efficacy and minimize complications.",[29],"2026-04-05",{"date":348,"type":51},"2026-04-13",{"date":350,"type":51},"2025-12-02",{"date":352,"type":22},"2026-12",{"name":354,"class":58},"Beni-Suef University",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":382,"leadSponsor":383,"locationsCount":59},"100632657","diss-vs-fans-in-suction-assisted-rirs-for-medium-sized-renal-stones-100632657","NCT07516535","DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones","The Impact of Suction-Assisted RIRS (DISS Versus FANS) on Postoperative Infection Rate and Stone-Free Rate After Treatment of Medium Sized Renal Stones","Inclusion Criteria:\n\n* Adults aged 18 to 60 years\n* Radiologically confirmed renal stones measuring 2 to 3 centimeters\n* Eligible for retrograde intrarenal surgery\n* Normal renal function as evidenced by normal serum creatinine\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Active urinary tract infection at the time of enrollment\n* Bleeding disorders or coagulopathies that contraindicate surgical intervention\n* Anatomical malformations affecting the urinary tract\n* Solitary kidney\n* Inability or unwillingness to provide informed consent","60 Years",{"count":364,"type":22},126,[25],"Kidney stones are a common health problem and may recur frequently, which can affect quality of life and kidney function. Retrograde intrarenal surgery (RIRS) is a minimally invasive treatment used for renal stones, but treatment of medium-sized stones may be associated with longer operative time, impaired visibility during surgery, residual stone fragments, and postoperative infectious complications caused by increased intrarenal pressure.\n\nSuction-assisted retrograde intrarenal surgery (RIRS) techniques have been developed to improve surgical efficiency and safety by facilitating continuous removal of stone fragments and helping control intrarenal pressure. Two commonly used suction-assisted approaches are direct in-scope suction (DISS) and flexible and navigable suction ureteric access sheath (FANS). However, there is limited prospective randomized evidence directly comparing these two techniques.\n\nThis randomized prospective clinical study aims to compare direct in-scope suction (DISS) versus flexible and navigable suction ureteric access sheath (FANS) in adult patients with medium-sized renal stones measuring 2 to 3 cm who are undergoing retrograde intrarenal surgery (RIRS). Participants will be randomly assigned to one of the two suction-assisted techniques. The study will evaluate whether flexible and navigable suction ureteric access sheath (FANS) provides better outcomes than direct in-scope suction (DISS) in terms of stone-free rate and postoperative infection rate.\n\nThe primary outcome is stone-free status assessed by postoperative imaging. Secondary outcomes include operative time, intraoperative visibility, and postoperative complications, particularly infection and urosepsis. The study hypothesis is that suction-assisted retrograde intrarenal surgery (RIRS) using the flexible and navigable suction ureteric access sheath (FANS) technique will result in a higher stone-free rate and a lower postoperative infection rate compared with direct in-scope suction (DISS) in the management of medium-sized renal stones.",[97,29,318],[369,370,371,372,373,374,375,376,377,235],"Retrograde Intrarenal Surgery","Suction-Assisted Retrograde Intrarenal Surgery","Medium-Sized Renal Stones","Stone-Free Rate","Postoperative Infection","Urosepsis","Flexible Ureteroscopy","Holmium Laser Lithotripsy","Ureteric Access Sheath","2026-04-01",{"date":380,"type":51},"2026-04-08",{"date":263,"type":22},{"date":302,"type":22},{"name":384,"class":58},"Ain Shams University",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":400,"leadSponsor":402,"locationsCount":59},"100632489","fans-vs-cvac-for-medium-to-large-stones-100632489","NCT07514351","FANS vs CVAC for Medium to Large Stones","Randomized Controlled Trial of Flexible and Navigable Suction (FANS) vs. CVAC Suction Ureteroscope for Medium to Large Stones","Inclusion Criteria:\n\n* Clinical diagnosis of Nephrolithiasis\n* Total linear stone diameter 8-20 mm in size\n\nExclusion Criteria:\n\n* Severe medical comorbidities causing inability to undergo general anesthesia",{"count":393,"type":22},159,[25],"Improvements in ureteroscopes have led to improved stone free rates. Two new devices (FANS - Flexible and Navigable Suction) and the CVAC ureteroscope have never been compared head to head. This trial will compare these two new suction ureteroscope technologies against each other",[97,29],"2026-03-31",{"date":300,"type":51},{"date":193,"type":22},{"date":401,"type":22},"2028-12",{"name":403,"class":58},"Ohio State University",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":426,"leadSponsor":427,"locationsCount":4},"100628157","erector-spinae-plane-block-for-percutaneous-nephrolithotomy-100628157","NCT07457983","Erector Spinae Plane Block for Percutaneous Nephrolithotomy","Perioperative Efficacy of Erector Spinae Plane Block in Patients Undergoing Percutaneous Nephrolithotomy","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n* Scheduled for elective percutaneous nephrolithotomy under general anesthesia.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* ASA physical status III-IV.\n* Refusal to participate in the study.\n* Known allergy or contraindication to local anesthetics (bupivacaine), opioids, or study medications.\n* Coagulopathy or anticoagulant therapy contraindicating regional block.\n* Infection at the injection site.\n* Severe psychiatric or cognitive disorder precluding reliable pain assessment or questionnaire completion.",{"count":412,"type":22},60,[25],"Percutaneous nephrolithotomy (PCNL) is an effective standard urological procedure for the fragmentation and removal of large renal calculi. Although PCNL is performed as a minimally invasive technique, dilation of the renal capsule and parenchymal tract, as well as peritubular distension caused by the nephrostomy tube, may result in severe postoperative pain. Various analgesic strategies have been described in the literature for postoperative pain management following PCNL. These include systemic opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and several regional analgesia techniques. However, due to their adverse effect profiles, opioids and NSAIDs are not ideal options, particularly in patients with renal dysfunction. Regional techniques that have been utilized include local infiltration, intercostal nerve blocks, paravertebral blocks, and epidural analgesia.\n\nThe kidney is primarily innervated between the T10 and L1 segments, whereas the ureter receives innervation from T10 to L2. Based on this anatomical knowledge, unilateral regional blockade between T10 and L2 can provide adequate analgesia for PCNL procedures. Thoracic paravertebral block was previously a commonly preferred technique; however, it may be associated with complications such as intravascular injection, unintended epidural or intrathecal spread, and pneumothorax during its performance. In recent years, the number of reports describing the use of the erector spinae plane block (ESPB) as part of multimodal anesthesia for postoperative analgesia has increased. In ESPB, local anesthetic is injected into the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, and has been reported to spread to multiple paravertebral spaces. ESPB is considered a peri-paravertebral block that can affect both visceral and somatic pain pathways.\n\nThe aim of this study is to evaluate the effect of ultrasound-guided erector spinae plane block on intraoperative and postoperative opioid consumption, postoperative pain scores, and quality of recovery in patients undergoing percutaneous nephrolithotomy.",[416,29,318],"Percutaneous Nephrolithotomy (PCNL)",[96,418,419,420,421],"Erector spinae plane block","Opioid consumption","Numerical pain scores (NRS)","Recovery quality (QoR-15T)","2026-03-09",{"date":424,"type":51},"2026-03-11",{"date":378,"type":22},{"date":104,"type":22},{"name":428,"class":58},"Fadime Tosun",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":59},"100623213","metaphylaxis-of-infected-kidney-stones-after-percutaneous-nephrolithotripsy-100623213","NCT07393711","Metaphylaxis of Infected Kidney Stones After Percutaneous Nephrolithotripsy","Evaluation of the Effectiveness of Intrarenal Dioxidine Metaphylaxis for Preventing Recurrence of Infection Stones After Percutaneous Nephrolithotripsy","DIOX-PCNL","Inclusion Criteria:\n\nAge ≥18 years\n\nPatients undergoing percutaneous nephrolithotripsy (PCNL)\n\nInfection-related kidney stones\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\nAge \\\u003C18 years\n\nPregnancy or breastfeeding\n\nKnown hypersensitivity to dioxidine\n\nSevere renal insufficiency or end-stage renal disease\n\nSevere comorbid conditions that preclude participation",{"count":438,"type":22},95,[25],"Kidney stone recurrence, particularly infection-related stones, remains a significant clinical problem after percutaneous nephrolithotripsy (PCNL). Bacterial colonization and persistent infection are recognized contributors to stone recurrence.\n\nThis study evaluates the effectiveness of intrarenal dioxidine instillation as a metaphylactic measure to reduce recurrence of infection-related kidney stones following PCNL. Patients undergoing PCNL will receive standard treatment, with or without adjunctive intrarenal dioxidine administration. The study aims to assess whether this approach reduces stone recurrence and infection-related complications.",[30,29,284],[443,95,444,445,446,447,448,449],"Percutaneous nephrolithotomy","Infection stones","Struvite stones","Dioxidine","Intrarenal instillation","Stone recurrence","Metaphylaxis","2026-02-08",{"date":452,"type":51},"2026-02-11",{"date":454,"type":22},"2026-03-01",{"date":456,"type":22},"2026-12-30",{"name":458,"class":58},"West Kazakhstan Marat Ospanov Medical University",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":470,"conditions":471,"keywords":473,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":489},"100624318","phase-1-sodium-bicarbonate-as-an-alternative-to-potassium-citrate-for-kidney-stones-100624318","NCT07408076","Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones","Inclusion Criteria:\n\n* Adult \\>18 years of age\n* History of nephrolithiasis\n* One 24h urine collections within one year of enrollment with hypocitraturia.\n* Patients currently utilizing or considering use of Kcit for stone prevention\n\nExclusion Criteria:\n\n* Individuals with known metabolic disorders\n* Individuals with other known causes of nephrolithiasis\n* Anyone who, in the opinion of the PI, is unfit or unsuitable to participate in the study",{"count":466,"type":22},30,[468,469],"PHASE1","PHASE2","Kidney stones affect 1 in every 11 people in the US each year. In patients with kidney stones who are prescribed medications for stone management, only 30.2% are adherent to a medication regime and even fewer, only 13.4 % are adherent with citrate medications.\n\nPrescription potassium citrate can be expensive for many patients, leading to non-compliance. Sodium bicarbonate is a potential medication alternative that is cheaper and can potentially alkalinize the urine and\u002For decrease the risk of future kidney stones. However, efficacy of alternatives to potassium potassium citrate are not well studied.\n\nThis study seeks to evaluate sodium bicarbonate and assess its ability to alkalinize urine in a cohort of patients with kidney stones and compare this to prescription potassium citrate.",[472,29],"Kidney Stones, Urolithiasis, Hypocitraturia",[256,474,475,476,477,478,479],"stone","calcium oxalate","calcium phosphate","potassium citrate","sodium bicarbonate","nephrolithiasis","2026-02-05",{"date":482,"type":51},"2026-02-12",{"date":484,"type":22},"2026-02-01",{"date":486,"type":22},"2028-02-01",{"name":488,"class":58},"University of California, Los Angeles",6,{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":362,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":503,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":510,"leadSponsor":512,"locationsCount":59},"100620648","comparison-between-different-types-of-flexible-ureteroscopes-100620648","NCT07360353","Comparison Between Different Types of Flexible Ureteroscopes","A Comparative Study of Performance and Cost-effectiveness of Three Different Single-Use Flexible Ureteroscopes in the Management of Renal Stones: A Randomized Clinical Trial","FURS","Inclusion Criteria:\n\n* Patients aged 18 to 60 years.\n* Presence of renal stones measuring less than 20 millimeters (mm).\n\nExclusion Criteria:\n\n* Renal stones larger than 20 millimeters (mm).\n* Uncontrolled bleeding disorders or coagulopathies.\n* Active urinary tract infection.\n* Renal failure.\n* Uncontrolled diabetes mellitus, hypertension, or hepatic dysfunction.\n* Pregnancy.\n* Abnormal urinary tract anatomy or known ureteric stricture.\n* History of previous open ureteric surgery.",{"count":499,"type":22},180,[25],"The current study aims to compare the performance of three distinct single-use digital flexible ureteroscope types in terms of cost-effectiveness, postoperative complications, operating time, and stone-free rates (SFRs).",[318,29],[33,504,505],"Single-use flexible ureteroscope","Renal stones","2026-01-25",{"date":508,"type":51},"2026-01-27",{"date":506,"type":51},{"date":511,"type":22},"2026-09-01",{"name":384,"class":58},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":520,"enrollmentInfo":521,"targetDuration":523,"studyType":524,"phases":4,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":536,"locationsCount":59},"100612847","postoperative-analgesia-practices-after-percutaneous-nephrolithotomy-100612847","NCT07258901","Postoperative Analgesia Practices After Percutaneous Nephrolithotomy","Optimizing Postoperative Pain Management After Percutaneous Nephrolithotomy: A Comparative Clinical Assessment","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* ASA physical status I-III\n* Undergoing unilateral PCNL\n* Providing written informed consent\n\nExclusion Criteria:\n\n* Known allergy to local anesthetics\n\nCoagulopathy or contraindication to regional anesthesia\n\nBMI \\> 35 kg\u002Fm²\n\nCognitive or communication impairment affecting pain evaluation\n\nNeurological or psychiatric disorders\n\nMusculoskeletal abnormalities\n\nChronic opioid use, alcohol or substance abuse history\n\nPrevious PCNL or open renal surgery on the same side\n\nRefusal to participate","65 Years",{"count":522,"type":22},75,"1 Day","OBSERVATIONAL","This prospective observational study aims to evaluate the effectiveness and safety of different postoperative analgesia methods used in patients undergoing percutaneous nephrolithotomy (PCNL). Analgesia techniques are determined independently by the responsible anesthesiologist as part of routine clinical practice, and the study team does not intervene in treatment decisions.",[29],[96,528,529,530,29],"Postoperative Analgesia","Pain Management","Regional Anesthesia","2025-12-01",{"date":350,"type":51},{"date":531,"type":22},{"date":535,"type":22},"2026-08-02",{"name":537,"class":58},"Istinye University",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":18,"minAge":545,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":524,"phases":4,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":557,"leadSponsor":559,"locationsCount":139},"100608449","is-cyp24a1-heterozygosity-a-risk-factor-for-nephrolithiasis-100608449","NCT07201701","Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?","HETEROCYP","Inclusion Criteria:\n\nGroup 1: Heterozygous Patients\n\n* Aged between 2 and 90 years\n* Weight \\> 12 kg\n* Carriers of a heterozygous CYP24A1 mutation\n* With or without symptoms: history of nephrocalcinosis or kidney stones\n\nGroup 2: Homozygous \u002F Compound Heterozygous Patients\n\n* Aged between 2 and 90 years\n* Weight \\> 12 kg\n* Carriers of a homozygous or compound heterozygous CYP24A1 mutation\n* With or without symptoms: history of nephrocalcinosis or kidney stones\n\nExclusion Criteria:\n\n* Individuals unable to collect 24-hour urine\n* Individuals unable to be available for a full day in a day hospital (HDJ)\n* Pregnant, postpartum, or breastfeeding women\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals receiving psychiatric care\n* Individuals admitted to a healthcare or social institution for reasons other than participation in research\n* Adults under legal protection (guardianship or trusteeship)\n* Individuals not affiliated with a social security system or not benefiting from an equivalent scheme","2 Years","90 Years",{"count":548,"type":22},45,"Biallelic loss-of-function variants in CYP24A1 have been identified as a common genetic cause of autosomal recessive hypercalcemia (ARH, ORPHA 300547, 1 in 80,000 live births), characterized by low PTH (parathyroid hormone) levels, a high 25-OH D\u002F24,25-(OH)₂D ratio, and susceptibility to vitamin D intoxication.\n\nIn humans, heterozygous pathogenic variants in CYP24A1 have been proposed both as responsible for an autosomal dominant disorder and as a risk factor for nephrolithiasis, but the rarity and heterogeneity of human data prevent a definitive answer to this crucial question.\n\nNephrolithiasis is a complex disease in which nutritional factors - particularly sodium and protein intake (leading to hypercalciuria) - play a key role. It also has a heritability of 50%, suggesting the involvement of many genetic susceptibility factors, as well as monogenic forms (mainly autosomal recessive, but also dominant or X-linked), which have been identified in 10-20% of patients.\n\nThe increasing prevalence of nephrolithiasis, affecting approximately 10% of the general population over a lifetime, has a significant financial impact on healthcare systems and imposes a major burden of morbidity, justifying further investigation into the genetic underpinnings of nephrolithiasis.\n\nThe goal of the HeteroCYP project is to improve understanding of the phenotypes associated with heterozygous, compound heterozygous, and homozygous variants of CYP24A1 by comparing clinical and biological outcomes in patients according to their mutation type",[29],[552,29,553,285],"CYP24A1 heterozygous","CYP24A1 homozygous, and compound heterozygous","2025-11-24",{"date":350,"type":51},{"date":531,"type":22},{"date":558,"type":22},"2028-04-01",{"name":560,"class":58},"Hospices Civils de Lyon",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":520,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":59},"100613085","comparison-of-extracorporeal-shock-wave-lithotripsy-versus-retrograde-intrarenal-surgery-in-the-management-of-renal-calculi-100613085","NCT07261995","Comparison of Extracorporeal Shock Wave Lithotripsy Versus Retrograde Intrarenal Surgery in the Management of Renal Calculi","Comparison of Outcomes of Extracorporeal Shock Wave Lithotripsy Versus Retrograde Intrarenal Surgery in the Management of Renal Calculi Measuring 1 to 2 Centimeters","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years.\n* Patients diagnosed with a single renal calculus measuring between 1 cm and 2 cm, confirmed on imaging (ultrasound or non-contrast CT KUB).\n\nExclusion Criteria:\n\n* Presence of multiple renal stones or bilateral renal stones.\n* Patients with anatomical abnormalities such as horseshoe kidney, ureteropelvic junction obstruction, or calyceal diverticulum based on medical history or radiological findings.\n* Active urinary tract infection at the time of intervention.\n* Pregnant women.\n* Patients with bleeding disorders or on anticoagulation therapy that cannot be safely stopped.\n* Patients with chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Patients with morbid obesity (BMI \\> 40 kg\u002Fm²).\n* Patients with solitary kidney.",{"count":569,"type":22},98,[25],"This study is being carried out in patients with kidney stones measuring between 1 and 2 centimeters. Kidney stones are common in Pakistan and can cause severe pain, infection, and repeated hospital visits. Two commonly used treatments for stones of this size are extracorporeal shock wave lithotripsy (ESWL) and retrograde intrarenal surgery (RIRS). ESWL uses shock waves applied from outside the body to break the stone into small fragments that can pass in the urine. RIRS is a minimally invasive endoscopic procedure in which a thin flexible scope is passed through the urinary passage into the kidney and a laser is used to break the stone.\n\nAdult patients aged 18 to 65 years with a single kidney stone of 1-2 cm will be included. According to the urologist's clinical judgment and patient preference, individuals will undergo either ESWL (Group A) as a day-care shock wave procedure or RIRS (Group B) under general anesthesia using a laser. All patients will receive standard care before and after the procedure and will be followed for 28 days.\n\nThe study will compare how completely the stone is cleared (based on a CT scan), how long patients stay in hospital, how much pain they feel after the procedure, and whether they develop visible blood in the urine or signs of infection such as fever and raised white cell count. The need for any further procedure for the same stone will also be recorded. The central hypothesis is that there is a meaningful difference between ESWL and RIRS in stone clearance, safety, pain, and need for retreatment. The findings are expected to help doctors and patients choose the most suitable treatment for kidney stones of this size in routine practice.",[29,318],[574,29,28,575,34],"Kidney stones","Extracorporeal shock wave lithotripsy","2025-11-21",{"date":578,"type":51},"2025-12-03",{"date":580,"type":51},"2025-09-05",{"date":480,"type":22},{"name":583,"class":58},"Ziauddin Hospital",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":116,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":59},"100564954","phase-2-intravesical-bupivacaine-on-post-operative-ureteroscopy-pain-100564954","NCT06635889","Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain","Double-Blind Randomized Placebo Controlled Trial of Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, aged ≥ 18 years old.\n* Diagnosis of nephrolithiasis planned for flexible or semi-rigid ureteroscopy in the treatment of stone disease with ureteral stenting.\n\nExclusion Criteria:\n\n* Foley catheterization\n* History of allergy to bupivacaine\n* Antegrade ureteroscopy\n* Transplant or ectopic kidney\n* Ureteral or bladder reconstruction\n* Pregnancy (which is a contraindication to elective ureteroscopy)\n* Dialysis\n* Surgical complication (significant bleeding, ureteral perforation, significant urothelial damage)\n* Suspicion of untreated urinary tract infection\n* History of pelvic radiation\n* Neurologic disease with a diagnosis of neurogenic bladder dysfunction\n* History of chronic pain (fibromyalgia, interstitial cystitis, opioid abuse)",{"count":592,"type":22},116,[469],"Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy.\n\nThis is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.",[29],"2025-11-06",{"date":598,"type":51},"2025-11-10",{"date":600,"type":51},"2025-03-26",{"date":602,"type":22},"2029-10",{"name":604,"class":58},"University of Chicago",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":59},"100552180","comparison-between-ureterorenoscopy-with-lithotripsy-alone-versus-combination-with-hydrogel-for-kidney-stone-removal-100552180","NCT06469736","Comparison Between Ureterorenoscopy With Lithotripsy Alone Versus Combination With Hydrogel for Kidney Stone Removal","Standard of Care Ureterorenoscopy With Lithotripsy Versus in Combination With the Hydrogel Method for Kidney Stone Removal: An Open, Randomized, Monocentric Study","Inclusion Criteria:\n\n* Male or female subjects aged ≥ 18 years\n* Evidence of nephrolithiasis on presentation of a preoperative computer tomography (CT) scan not older than 6 months\n* Minimum size of the kidney stones defined as \\>10mm in the longest axis in the preoperative CT.\n* Ability to read, write and speak German\n* Women of childbearing age must have a negative serum pregnancy test at the start of the study.\n* Submission of a personally signed and dated informed consent form stating that the subject has been informed of all relevant aspects of the study prior to any trial-related activity and that all information has been understood\n\nExclusion Criteria:\n\n* Participation in another clinical trial for kidney stone removal in the last 6 months\n* Subjects with gastrointestinal cancer who have not been in remission for at least 2 years\n* Subjects with a single kidney, horseshoe kidney or other anatomical abnormalities that may increase the risk of surgery for the subject\n* Subjects with untreated ureteral stenosis or renal stenosis and narrow ureteropelvic junction\u002Fureterovesical junction\n* Subjects with known impaired renal function from stage IV or known dialysis\n* Subjects with chronic hydronephrosis not associated with nephrolithiasis\n* Subjects with the following known or suspected diseases: Coagulation disorders, untreated urinary tract infections, renal disease sepsis and marked prostatic hyperplasia\n* Subjects with any other disease or condition that, in the opinion of the investigator, could interfere with the purpose of the study (e.g. bleeding that restricts vision in the kidney, problems in the renal tubular system)\n* Breastfeeding or pregnant women\n* Subjects who may be part of a vulnerable group (e.g. prisoners or developmentally delayed adults)",{"count":613,"type":22},120,[25],"The incidence of kidney stones (urolithiasis) has surged in both developing and developed countries, affecting approximately 15% of the global population. From 2010 to 2019, diagnoses of kidney and ureteral stones rose by 8% in Germany, 26% in France, and 15% in England. Correspondingly, the number of surgical stone removal procedures increased by 3%, 38%, and 18%, respectively. Common treatments include extracorporeal shock wave lithotripsy (ESWL), ureterorenoscopy (URS) with lithotripsy, and percutaneous nephrolithotomy (PCNL).\n\nURS, depending on stone size, has become a preferred method due to advancements in intraoperative imaging and laser technology. Despite these improvements, small fragments often remain post-intervention, leading to recurrent stones. Complete removal of all fragments is crucial to significantly reduce recurrence rates. Current literature suggests a high recurrence rate with residual fragments, impacting healthcare costs and patient quality of life.\n\nA key objective in endourological research is optimizing the stone clearance rate. Techniques like coagulum lithotomy and the autologous blood clot technique have been developed to enhance residual stone removal after laser fragmentation. These methods benefit selected patients but are not widely adopted due to complications such as reduced intraoperative visibility and long coagulum formation times.\n\nRecently, a two-component hydrogel system called mediNiK® (Purenum GmbH, Germany) was developed. This biocompatible gel can be applied through an endoscope after stone fragmentation and large fragment retrieval to embed smaller fragments and dust, forming a removable conglomerate. MediNiK® has demonstrated effectiveness in embedding and removing stone residues and is already in clinical use in Europe, showing potential for optimizing stone removal.\n\nA multicenter study has assessed the safety and tolerability of mediNiK® in standard URS (Open, randomized, multicentre study to evaluate the safety, tolerability, and performance of mediNiK® compared to standard treatment in kidney stone removal - DRKS00030532). Results indicate the gel is safe and tolerable. However, further data from larger cohorts and comparisons with conventional URS are necessary before widespread adoption of mediNiK®.",[29,617,31],"Lithotripsy, Laser",[619,620,621,622,623,624,625,626,627,628],"Hydrogel","MediNiK","Hydrogel methode","Stone Free Rate","Zero Residual Fragments","URS","Dusting","Stone free","Thulium","Kidneystones","2025-09-02",{"date":631,"type":51},"2025-09-09",{"date":633,"type":51},"2024-07-01",{"date":635,"type":22},"2026-07-30",{"name":637,"class":58},"Technical University of Munich",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":524,"phases":4,"briefSummary":645,"conditions":646,"keywords":647,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":59},"100413922","serum-endotoxin-assay-to-predict-the-development-of-postoperative-infectious-complications-and-systemic-inflammatory-response-following-percutaneous-nephrolithotomy-100413922","NCT04669886","Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.","Inclusion Criteria:\n\n* Adults that is able to consent (≥ 18 years of age)\n* Scheduled to undergo PCNL at Uhealth tower and Jackson Memorial Hospitals\n* not currently immunosuppressed \\[White blood count (WBC) \\>= 2, not on immunosuppressive medications\\]\n\nExclusion Criteria:\n\n* unable to consent and \\\u003C 18 years of age\n* currently immunosuppressed (WBC \\\u003C 2, not on immunosuppressive medications)",{"count":207,"type":22},"The aim of the study is to establish an infectious risk stratification system based on pre-and post-operative blood endotoxin profile.",[29,374],[648,649,324,650,651],"endotoxin","fever","endourology","percutaneous nephrolithotomy","2025-09-01",{"date":654,"type":51},"2025-09-03",{"date":656,"type":51},"2023-11-01",{"date":658,"type":22},"2026-12-01",{"name":660,"class":58},"University of Miami"]